The Oklahoma Medical Research Foundation is preparing the second
in a series of free public lectures demonstrating how scientific
research results in new and more effective drugs, treatments and
Entitled "From Bench to Bedside: Biomedicine at the New
Millennium," the lectures will feature nationally and
recognized biomedical research scientists on such topics as cancer,
heart disease, stroke, Alzheimer's, genetic and autoimmune diseases,
diabetes and others.
Dr. Brian Sauer, the new head of OMRF's Developmental Biology
Research Program, will present "Genetic Engineering: Clues to Human
Disease" on April 29. One of the world's leading genetic engineers,
the former National Institutes of Health scientist will discuss how
learning the entire sequence of human DNA -- a large part of the
Human Genome Project, which will be completed in a few years -- will
help determine the basis of human genetic diseases and lead to the
development of effective therapeutic remedies.
The Developmental Biology Research Program is the first new
research program at OMRF in more than a decade, and has been funded
in part by a $3 million grant from the Noble Foundation of Ardmore.
On May 13, Dr. Linda Thompson, a leader in cancer research and a
scientific member of the Immunobiology and Cancer Research Program
OMRF, will present "Breakthrough Discoveries in Breast Cancer
Research." She will center on how a new gene discovery in her
laboratory is leading to potential new ways of assessing breast
cancer risk and providing insight into developing new treatments.
She will also talk about the importance of genes Her-2/neu and BRCA1
and 2 and how major advances are now being made in molecular biology
in the study of breast cancer.
Dr. Jordan Tang, the J.G. Puterbaugh Chair in Medical Research --
world renowned for his research on human proteins and important AIDS
discoveries -- will present "AIDS: The Race for Treatment or Cure"
May 25. Tang will provide a world-view update on the disease, and
look at new therapies that may emerge from current research,
including his own discoveries.
"The idea for this lecture series was conceived for two purposes,"
said Dr. J. Donald Capra, OMRF president. "One, so that the public
can become more aware of the biomedical research activities going on
in Oklahoma, and two, to give back in some small measure to the
people throughout the state who have so generously given to OMRF
All lectures will be presented at 4 p.m. in the Wileman Auditorium
at OMRF, 825 NE 25th St. Founded in 1949 as a private, nonprofit
biomedical research institute, the OMRF employs about 38 scientists
and more than 350 scientific staff, administrative and other support
Dr. Robert A. Wild, the chief of reproductive endocrinology and
infertility at the University of Oklahoma Department of Obstetrics
and Gynecology, has been named to the National Institutes of Health
Advisory Committee on Research on Women's Health.
Dr. Thomas R. Coughlin Jr. has been appointed medical director of
Maxxon, the Tulsa company developing a one-handed disposable safety
syringe with a retracting needle to prevent accidental needlestick
injuries. Coughlin, a graduate of Seton Hall and the University of
Rochester School of Medicine, came to Maxxon from serving as an
associate of Dr. Bill Loughridge. Maxxon expects to have the initial
pilot production run of its syringe in a few weeks.
The Oklahoma State Department of Health has proposed new rules on
such areas as body piercing, food service establishments, fee
schedules for environmental health services, adult day care and
nursing center pets, health maintenance organization physician
review, hospice fees, continuum of care and assisted living center
fees and Alzheimer's Disease disclosure rules. …